1/11
06:05 pm
zntl
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Progress And Insider Buying [Yahoo! Finance]
High
Report
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Progress And Insider Buying [Yahoo! Finance]
1/6
08:00 am
zntl
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026
High
Report
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026
12/17
09:29 am
zntl
Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell [Yahoo! Finance]
Low
Report
Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell [Yahoo! Finance]
11/18
04:04 pm
zntl
Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval [Seeking Alpha]
Low
Report
Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval [Seeking Alpha]
11/16
01:10 am
zntl
Zentalis Pharmaceuticals (NASDAQ:ZNTL) was upgraded by analysts at
Wall
Low
Report
Zentalis Pharmaceuticals (NASDAQ:ZNTL) was upgraded by analysts at
Wall
11/12
12:34 pm
zntl
Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target lowered by analysts at Morgan Stanley from $8.00 to $4.00. They now have an "equal weight" rating on the stock.
Low
Report
Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target lowered by analysts at Morgan Stanley from $8.00 to $4.00. They now have an "equal weight" rating on the stock.
11/11
10:08 am
zntl
Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.
Medium
Report
Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.
11/11
07:03 am
zntl
Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its "market perform" rating reaffirmed by analysts at Leerink Partners.
Medium
Report
Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its "market perform" rating reaffirmed by analysts at Leerink Partners.
11/10
04:05 pm
zntl
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
Medium
Report
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
11/3
05:25 pm
zntl
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/3
08:15 am
zntl
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Medium
Report
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
10/24
12:27 pm
zntl
Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.